Mercer Global Advisors Inc Blueprint Medicines Corp Transaction History

Mercer Global Advisors Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 04, 2022	SELL	$94.25 - $115.99 $245,992 - $302,733	-2,610 Closed	0 $0
Q3 2021 Nov 10, 2021	BUY	$80.98 - $109.47 $211,357 - $285,716	2,610 New	2,610 $268,000
Q2 2021 Aug 10, 2021	SELL	$82.78 - $101.0 $241,220 - $294,314	-2,914 Closed	0 $0
Q1 2021 May 11, 2021	BUY	$90.71 - $108.28 $264,328 - $315,527	2,914 New	2,914 $283,000
Q3 2020 Dec 10, 2020	SELL	$66.45 - $92.7 $272,577 - $380,255	-4,102 Closed	0 $0
Q2 2020 Aug 10, 2020	BUY	$57.09 - $79.27 $234,183 - $325,165	4,102 New	4,102 $320,000

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Mercer Global Advisors Inc , based on Form 13F filings with the SEC.

Stay updated on Mercer Global Advisors Inc with notifications on news.